A first-in-human clinical trial evaluating an investigational gene therapy targeting complement-mediated pathways in ...
LONDON--(BUSINESS WIRE)--Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, today announced positive interim safety, protein expression and biomarker ...
-- First patient dosed in Phase II EXPLORE trial evaluating GT005 in people with geographic atrophy secondary to dry AMD with a mutation in the Complement Factor I gene -- -- A second Phase II trial ...
Philadelphia and Gordonville, PA, August 12, 2025 – Researchers from Children’s Hospital of Philadelphia (CHOP) and the Clinic for Special Children found that complement factor I (CFI) deficiency, an ...
Hosted on MSN
Research reveals rare form of neuroinflammatory disease is more common in Old Order Amish than general population
Researchers from Children's Hospital of Philadelphia (CHOP) and the Clinic for Special Children found that complement factor I (CFI) deficiency, an ultra-rare genetic disorder that can cause ...
Please provide your email address to receive an email when new articles are posted on . In a first-in-human phase 1/2 study, GT005, an AAV2-based one-time investigational gene therapy, showed ...
Objective SLE is a systemic autoimmune disease in which the complement system plays a key pathogenic role, yet the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results